BBC0403

SKU: orb2564575

Description

BBC0403 is a selective BRD2 inhibitor that suppresses NF-κB and MAPK signaling pathways. It has demonstrated utility in osteoarthritis (OA) research, showing potential in both in vitro cellular models and in vivo studies of joint inflammation and cartilage degradation.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 2644662-83-7
• MW: 382.41
• Purity: 98.15%
• Formula: C₂₁H₂₂N₂O₅
• SMILES: O=C1N=C(NC=2C=C(OC)C=C(OC)C12)C=3C=C(C(OC4COC4)=C(C3)C)C
• Target: Epigenetic Reader Domain
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.23 mM);DMSO:20 mg/mL (52.3 mM)

Bioactivity

• Target IC50:
  BRD2 (BD1):41.37 μM (Kd)|BRD2 (BD2):7.64 μM (Kd)
• In Vivo:
  Weekly intra-articular injection of 5-10 μg/kg of BBC0403 for 6 weeks effectively prevented the degradation of osteoarthritic cartilage in a mouse model.
• In Vitro:
  BBC0403 is a selective BRD2 inhibitor with Kd values of 7.64 μM for BRD2 (BD2) and 41.37 μM for BRD2 (BD1).BBC0403 significantly inhibited the expression of catabolic factors, the production of prostaglandin E2 (PGE2) and the degradation of the extracellular matrix (ECM) after treatment with BBC0403 at 5 μM, 10 μM, and 20 μM for 12 h. BBC0403 inhibits catabolic factor expression, prostaglandin E2 (PGE2) production, and the degradation of ECM. and extracellular matrix (ECM) degradation. By blocking the NF-κB and MAPK signaling pathways, BBC0403 helps to alleviate the development of osteoarthritis (OA).

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BBC 0403

Compound Identifiers

PubChem CID

171037449